Pharma

DEA OKs synthetic marijuana for pharma company that spent $500,000 to keep pot illegal

Insys Therapeutics, a pharmaceutical company that was one of the chief financial backers of the opposition to marijuana legalization in Arizona last year, received preliminary approval from the Drug Enforcement Administration this week for Syndros, a synthetic marijuana drug.<p>Insys gave $500,000 …

Marijuana

Premarket analyst action - healthcare

Verastem reiterated with Buy rating and $6.50 (328% upside) price target by H.C. Wainwright.<p>Five Prime Therapeutics (NASDAQ:FPRX) and Syndax …

Stocks

FiercePharmaAsia—China’s foreign drug policy, Tessa’s deal, two Big Pharma chiefs’ globalization comments | FiercePharma

Welcome to this week’s FiercePharmaAsia report. China’s been in the spotlight these days as the country plots a major foreign drug policy overhaul, …

China

Struggling Teva said to plan up to 6,000 job cuts as it hunts for CEO

Changes are afoot at foundering Teva—and they include job cuts and a recruitment freeze.<p>Local media reports said Thursday that the Tel Aviv, …

Markets

Skill mix: Do practice pharmacists really make a difference?

I am a partner and pharmacist at the Tamar Valley practice, a successful rural practice with two sites nestled in the beautiful Tamar Valley in east …

Health Care

Pharma Gets Roped Into the Trumpcare Maelstrom - Bloomberg Gadfly

When you rush any kind of massive project, you raise the risk that people get hurt.<p>That's certainly the case with health-care reform. As President …

Health Care

Xenon Pharma's lead dermatology candidate flunks mid-stage acne study

Thinly traded micro cap Xenon Pharmaceuticals (NASDAQ:XENE) is poised for a down day after announcing that lead dermatology candidate XEN801 failed …

Dermatology

15. Bristol-Myers Squibb

<b>15. Bristol-Myers Squibb<br>Headquarters: New York City<br>2016 revenues: $19.427 billion<br>2015 revenues: $16.56 billion</b><p>By the numbers, Bristol-Myers Squibb …

Cancer

Lawmakers want to know PTC's pricing plans for ex-Marathon drug Emflaza

When PTC Therapeutics agreed to purchase Marathon's controversial drug Emflaza last week, it didn’t only get an FDA-approved treatment for Duchenne …

Valeant awarded CEO Papa $62.7M last year despite missing financial targets

Valeant is shelling out a hefty sum on its chief exec’s pay package for a pharma company—let alone a pharma company that’s struggling under a …

Markets

It's not just lower U.S. drug prices Trump wants. He wants the lowest, period

President Donald Trump is back with more drug-pricing promises. This time, he says he's aiming to push prices lower than anywhere else in the …

Health Care

Sanofi on verge of $1B-plus deal for arthritis-focused biotech Flexion: source

Sanofi is in talks to buy Flexion Therapeutics, a Boston-area biotech with its lead product now awaiting FDA approval, for more than $1 billion in …

Johnson & Johnson

Pharmacist acquitted of murder in deadly meningitis outbreak

BOSTON — A jury on Wednesday acquitted pharmacist Barry Cadden of murder charges in the deaths of 25 patients injected with steroids from his lab.<p>Cadden, however, was found guilty of racketeering, conspiracy and mail fraud charges. Some of the counts could bring a maximum sentence of 20 years. …

Crime

Are reverse auctions the best way to procure marketing services?

Managing Director Martin Brass discusses what a reverse auction is, and whether it truly is a good way for healthcare companies to drive efficiencies …

Health Care

Sanofi exec fires back amid fight over Zika vaccine license

After taking a beating over a proposed Zika vaccine license from the U.S. Army, Sanofi is hitting back. R&D chief Elias Zerhouni wrote a letter to …

Viruses

GSK starts $175M plant to boost production of vax star Bexsero

Vaccines have been one of the financial bright spots for GlaxoSmithKline and Bexsero, the vax it picked up in its asset swap with Novartis, has had …

Bellicum Pharma launches 5M-share equity offering; shares slip 3% after hours

Bellicum Pharmaceuticals (NASDAQ:BLCM) commences a public offering of 5M shares of common stock. Underwriters over-allotment is an additional 750K …

Business

Marijuana play Creso Pharma seeks to raise $4.8 million

Medicinal cannabis company Creso Pharma is seeking to raise $4.8 million with the help of EverBlu Capital.<p>The offer price of 69¢ represents a 16.4 …

Startups

Imprimis Pharma inks $3.1M direct capital raise; shares ease 8% premarket

Thinly traded nano cap Imprimis Pharmaceuticals (NASDAQ:IMMY) is off 8% premarket on light volume in response to its announcement that it has entered …

Business

Big Pharma finds a hit with disease awareness social media posts in 2016

Pharma marketers continued to up their social media game in 2016, according to a new report, with many embracing disease awareness and charitable …

Social Media Marketing

DTC #FierceMadness hits the Sweet 16 as Gut Guy, Irritabelle and show tunes bite the dust

DTC #FierceMadness' fast and furious two-day Round 2 matchups have carved the pharma ad field down to 16, with disease awareness emerging as a …

Morgan Freeman

Biogen sticks it to Kyle Bass with Tecfidera IPR win

Pharma patent challenger Kyle Bass has lost his second round at the U.S. Patent and Trademark Office in as many weeks, and this time, the win is …

Creso Pharma shares jump amid Brazil deal

Shares in Creso Pharma have jumped nearly 18 per cent after the cannabis-derived nutraceutical products maker signed an agreement to sell its …

Markets

Biotech Momentum Outweighs Pharma 'Red Flag' In ETF Upgrade

The <b>iShares Nasdaq Biotechnology Index</b> (IBB) exchange-traded fund pulled an upgrade Tuesday as investment bank Credit Suisse looks to get more …

Stocks

Eagle Pharma Cancer Drug Secures New Patents (EGRX)

Eagle Pharmaceuticals Inc. (EGRX) announced that the United States Patent and Trademark Office (USPTO) has issued three additional patents for its …

Personal Finance

Copying Valeant's Xifaxan just got 'a lot easier,' thanks to new FDA guidance: analyst

Valeant already has enough Xifaxan problems without more competition for its leading med. But thanks to the FDA, that competition may be on its way …

FDA

Eli Lilly says it's cutting an average of 50% off list prices—and its price hikes don't work

Heightened pressure from pharmacy benefit managers and increased competition among drugmakers are taking a big bite out of Eli Lilly's list-price …

Health Care

Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med

Novartis’ next-gen psoriasis med, Cosentyx, has picked up a couple of competitors since hitting the scene, and more are on the way. But the Swiss …

Johnson & Johnson

Sanofi, Regeneron ask court to shield Dupixent from Amgen patent attack

The last time Sanofi and Regeneron launched a drug together, Amgen sued for patent infringement. Now, with an FDA decision on their key drug Dupixent …

Patents

GeoVax pushes ahead in Zika vaccine realm with promising preclinical data

A new Zika vaccine candidate by GeoVax showed promise in preclinical tests on mice, and the company believes it could become “the best solution” to …

Viruses